40.67
+4.60%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Roivant Sciences
From its filings with the US Securities and Exchange Commission
Roivant Sciences is based in London and is incorporated in Bermuda. Its shares trade on Nasdaq under the ticker ROIV. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2026, it reported revenue of $8.3m and a net loss of $299.8m. At that date it held total assets of $5.71bn and shareholders' equity of $4.53bn.
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Note: All product candidates in our current pipeline are investigational and subject to health authority approval. The “Phase” for a specific product candidate referenced above reflects both ongoing clinical trials and expected upcoming trials.
Quoted from its 10-K, filed 20 May 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Dec 2020
- Employees
- 721
- Website
- roivant.com ↗
- Head office
- 7TH FLOOR, 50 BROADWAY, LONDON, SW1H 0DB
- Incorporated in
- D0
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Ilan OrenIndependent Chairman of the Board$521,547
- Dr. Mayukh SukhatmePresident, Chief Investment Officer, Director, since 2021$251.9m
- Mr. Matthew GlineChief Executive Officer, Director, since 2017$163.3m
- Mr. Richard PulikChief Financial Officer$4.1m
- Dr. Frank TortiPresident and Vant Chairman
- Dr. Eric VenkerPresident and Immunovant Chief Executive Officer$11.8m
- Ms. Jennifer HumesChief Accounting Officer$2.4m
- Ms. Melissa EpperlyIndependent Director$489,410
- Ms. Meghan FitzgeraldIndependent Director$482,910
- Mr. Daniel GoldIndependent Director$484,410
- Dr. Keith ManchesterIndependent Director$476,660
- Mr. James MomtazeeIndependent Director$473,844
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 13
- Social
- 32
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research and Development capabilities, enabling development of innovative drugs and therapies.
- Well-established partnerships with leading pharmaceutical companies, providing access to resources, expertise, and potential collaborations.
- Diverse portfolio of drug candidates across various therapeutic areas, reducing dependency on a single product.
Weaknesses
- Relatively small market presence compared to larger pharmaceutical companies, limiting brand recognition and market share.
- High dependence on external sources for funding research and development activities, making the company vulnerable to changes in funding availability.
- Limited manufacturing capabilities, potentially impacting the speed and efficiency of drug production.
Opportunities
- Growing demand for innovative and personalized healthcare solutions, creating opportunities for Roivant Sciences Ltd to capitalize on its R&D expertise.
- Expansion into emerging markets with favorable regulatory environments, allowing for increased market penetration.
- Potential collaborations with academic institutions and research organizations to further enhance R&D capabilities.
Threats
- Intense competition within the pharmaceutical industry, with larger players having significant resources and established market positions.
- Stringent regulatory requirements and lengthy approval processes, posing challenges and delays in bringing new drugs to market.
- Uncertainty surrounding healthcare policies and reimbursement systems, potentially impacting the demand and pricing of drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.